proposed a proof-of-concept study, they enrolled patients with NSCLC, uveal melanoma, or MSI CRC who were treated by nivolumab or pembrolizumab monotherapy, their results demonstrated that quantitative ctDNA monitoring can be used as a valuable tool to assess tumor patients’ response to anti-PD-1 agents (179). This evidence concerns the gene PDCD1 and colorectal carcinoma.